#United States #Morristown #Whitehawk Therapeutics #ADC Technologies #oncology therapeutics

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics, Inc., a prominent clinical-stage company focused on oncology therapeutics, is set to participate in the upcoming 2026 Stifel Virtual Targeted Oncology Forum. The event will take place virtually on May 19, 2026, at 3 PM ET and will feature a fireside chat with the company's President and CEO, Dr. Dave Lennon. This forum presents an opportunity for Whitehawk to share insights regarding its innovative approaches to cancer treatment, particularly through the use of advanced antibody drug conjugate (ADC) technologies.

About the Event

The virtual fireside chat will allow attendees to gain firsthand knowledge about the advancements Whitehawk Therapeutics is making in the field of oncology. Dr. Lennon will address the company's strategic developments and the impact of its state-of-the-art ADC portfolio, which aims to enhance the efficacy of treatments for difficult-to-treat cancers. Those interested can access a live webcast of the event through the Whitehawk Therapeutics Investor Relations (IR) website, where a replay will also be available for 30 days following the initial broadcast.

Whitehawk Therapeutics Overview

Whitehawk Therapeutics specializes in the development of innovative cancer therapies utilizing advanced technologies to target tumor biology effectively. The company is dedicated to delivering improved treatment options that promise a significant impact on patients' lives. At the core of its product development is an advanced three-asset ADC portfolio, which was engineered to overcome the shortcomings of earlier ADC generations. These assets are exclusively licensed from WuXi Biologics, under a robust development and global commercialization agreement aimed at meeting the unmet needs of cancer patients.

By harnessing the latest scientific advances and an understanding of tumor biology, Whitehawk aims to redefine the landscape of cancer treatment and enhance patient outcomes. The ongoing projects and developments at Whitehawk demonstrate a commitment to innovation that resonates within the oncology community, especially for individuals confronting major health challenges brought on by cancer.

Conclusion

As the healthcare landscape evolves, events like the 2026 Stifel Virtual Targeted Oncology Forum play a crucial role in bridging the gap between innovation and delivery of care. Whitehawk Therapeutics' participation underscores its commitment to advancing oncology therapeutics and easing the burden of cancer treatment through innovative technologies. For more details about the event and ongoing projects, visit Whitehawk Therapeutics and connect with them on LinkedIn to stay updated on their journey towards transforming cancer care.

Together, the healthcare community and biotech companies like Whitehawk Therapeutics are paving the way toward more effective cancer therapies, contributing to the hope of improved outcomes for patients globally.